PCM
ADPT icon

Pentwater Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Pentwater Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6,000
Closed -$290K – 158
2019
Q2 		$290K Buy
+6,000
New +$266K ﹤0.01% 169

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pentwater Capital Management's ADPT Position: Q3 2019 in Review

Pentwater Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2019, closing a stake of 6,000 shares — an estimated $290K sold.

Pentwater Capital Management first reported a position in ADPT in Q2 2019 and held it in 1 quarter. The position peaked at $290K in Q2 2019. 117 funds tracked by Wall St. Rank hold ADPT as of Q3 2019.

  • Pentwater Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2019 after selling out during the quarter.
  • Pentwater Capital Management sold 6,000 Adaptive Biotechnologies shares in Q3 2019, an estimated $290K.
  • Pentwater Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 1 quarter.
  • Pentwater Capital Management's Adaptive Biotechnologies position peaked at $290K in Q2 2019.
  • 117 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2019.

Based on Pentwater Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.